Shim, Man Kyu Song, Su Kyung Jeon, Seong Ik Hwang, Kwang Yeon Kim, Kwangmeyung 2024-01-19T12:01:12Z 2024-01-19T12:01:12Z 2022-06-17 2022-06 1742-5247 https://pubs.kist.re.kr/handle/201004/115146 Introduction Immune checkpoint blockade (ICB) therapy is now FDA-approved for the treatment of various tumor types. By removing inhibitory signals for T-cell activation and disrupting the immune escape mechanism of tumor cells, ICB therapy has shown considerable efficacy with complete tumor regression in patients. However, patients respond poorly to this therapy and show limited response rates owing to the immunosuppressive tumor microenvironment (ITM) in cold tumors. Areas covered In this review, recent advances and progress in the use of nano-sized drug delivery system (Nano-DDS) to potentiate the ICB therapy by reversing cold tumors with an ITM into immunogenic hot tumors are discussed. The types of immunogenic cell death (ICD) inducers that initiate or enhance antitumor immune responses are classified, and their extensive combination with immune modulators using Nano-DDS is highlighted. Expert opinion Nano-DDS can be efficiently combined with ICD inducers and immune modulators and trigger a potent antitumor immune response based on a comprehensive approach to the cancer-immunity cycle. English Ashley Publications Ltd. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy Article 10.1080/17425247.2022.2081683 1 Expert Opinion on Drug Delivery, v.19, no.6, pp.641 - 652 Expert Opinion on Drug Delivery 19 6 641 652 N scie scopus 000802988300001 Pharmacology & Pharmacy Pharmacology & Pharmacy Review IMMUNOGENIC CELL-DEATH MESOPOROUS SILICA NANOPARTICLES POLYSIALIC ACID NANOPARTICLES CANCER-IMMUNOTHERAPY RADIOTHERAPY COMBINATION ADJUVANTS PARADIGM TUMORS Nanomedicine drug delivery cancer immunotherapy immune checkpoint blockade combination therapy